The Technical Analyst
Lucira Health, Inc. [LHDX]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Lucira Health, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.452
America/New_York / 3 mar 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 18.36 mill |
| EPS: | -3.14 |
| P/E: | -0.144 |
| Earnings Date: | May 10, 2023 |
| SharesOutstanding: | 40.60 mill |
| Avg Daily Volume: | 21.45 mill |
| RATING 2023-03-30 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.144 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.144 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.389 - 0.515 ( +/- 13.93%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-03 | Engelson Erik T. | Buy | 574 666 | Common Stock |
| 2023-03-03 | Engelson Erik T. | Sell | 574 666 | Common Stock |
| 2023-03-03 | Engelson Erik T. | Sell | 60 000 | Common Stock |
| 2023-03-03 | Engelson Erik T. | Sell | 574 666 | Common Stock |
| 2023-03-03 | Narido Richard Clavano | Sell | 10 674 | Common Stock |
| INSIDER POWER |
|---|
| -77.64 |
| Last 96 transactions |
| Buy: 17 602 742 | Sell: 22 464 128 |
Forecast:
01:40 - $0.129
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.452 (0.00% ) |
| Volume | 36.26 mill |
| Avg. Vol. | 21.45 mill |
| % of Avg. Vol | 169.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LHDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LHDX
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Last 10 Buy Signals
Latest Press Releases
2022-08-23 07:00:00 - Press Release
Lucira Health To Present At The Inaugural Gilmartin Group Emerging Growth Company Showcase
Emeryville, calif., aug. 23, 2022 (globe newswire) -- lucira health, inc. (“lucira health” or “lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the gilmartin group emerging growth company showcase on august 31st, 2022.
2022-08-02 07:00:00 - Press Release
Lucira Health To Announce Second Quarter 2022 Financial Results
Emeryville, calif., aug. 02, 2022 (globe newswire) -- lucira health, inc. (“lucira health” or “lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, monday, august 15, 2022. lucira's management will host a conference call and webcast at 1:30 p.m. pt / 4:30 p.m. et that day to discuss the financial results and provide a corporate update.
2022-04-28 07:00:00 - Press Release
Lucira Health To Announce First Quarter 2022 Financial Results
Emeryville, calif., april 28, 2022 (globe newswire) -- lucira health, inc. (“lucira health” or “lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter 2022 financial results on thursday, may 12, 2022. lucira's management will host a conference call and webcast at 1:30 p.m. pt / 4:30 p.m. et that day to discuss the financial results and provide a corporate update.
2022-02-28 17:00:00 - Press Release
Lucira Health To Announce Fourth Quarter 2021 Financial Results
Emeryville, calif., feb. 28, 2022 (globe newswire) -- lucira health, inc. (“lucira health” or “lucira”) (nasdaq: lhdx), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report fourth quarter 2021 financial results on, thursday, march 10, 2022. lucira's management will host a conference call and webcast at 1:30 p.m. pt / 4:30 p.m. et that day to discuss the financial results and provide a corporate update.
2021-10-15 20:40:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Lucira Health, Inc. - Lhdx
New york, oct. 15, 2021 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of lucira health, inc. ("lucira" or the "company") (nasdaq: lhdx). such investors are advised to contact robert s.
Latest News
2023-03-03 09:36:06 - InvestorPlace
Why Is Lucira Health (LHDX) Stock Down 14% Today?
Lucira Health (NASDAQ: LHDX ) stock is falling on Friday after the company's shares have seen extreme volatility throughout the week. That includes a massive rally earlier this week that saw the company's shares gain as much as 871% since its closing price on Friday.
2023-03-01 06:01:28 - MarketBeat
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test. The over-the-counter (OTC) 30-minute at-home rapid test can detect influenza A and B and the SARS-CoV-2 virus using nasal swabs.
2023-03-01 06:00:00 - PennyStocks
Penny Stocks: The Importance of Liquidity and Volume
Using liquidity and volume to make money with penny stocks The post Penny Stocks: The Importance of Liquidity and Volume appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-28 12:20:18 - PennyStocks
Penny Stocks To Buy Now? 7 Under $5 To Watch Before Next Week
2023-02-27 10:34:49 - Proactive Investors
Lucira Health shares rise more than 300% on FDA authorization of at-home combination COVID-19 and flu test
Lucira Health Inc shares have added more than 300% after it announced on Friday that the US Food and Drug Administration (FDA) has granted emergency use authorization for its combination COVID-19 and flu test for use at home and in non-laboratory settings, just days after the company filed for Chapter 11 bankruptcy. The company said the molecular test delivers results in 30 minutes or less from a shallow nasal swab and demonstrated similar performance for COVID-19 and Influenza A and B compared to highly sensitive lab-based PCR tests in clinical trials.
2023-02-27 08:19:45 - InvestorPlace
Why Is Lucira Health (LHDX) Stock Up 237% Today?
Lucira Health (NASDAQ: LHDX ) stock is rocketing higher on Monday thanks to an update from the FDA. The big news here is Lucira Health getting FDA approval for its at-home Covid-19 and flu combination tests.
2023-02-24 17:28:00 - Market Watch
Lucira stock more than doubles after hours on FDA OK for COVID-19, flu test
Lucira Health Inc. LHDX, +13.45% shares more than doubled in the extended session Friday after the Food and Drug Administration authorized use of its at-home test that can detect both the flu and the virus that causes COVID-19. Shares of Lucira soared more than 150% after hours, following a regular session gain of 13.5% to close at 14 cents.
2023-02-23 08:42:30 - InvestorPlace
Why Is Lucira Health (LHDX) Stock Down 34% Today?
Lucira Health (NASDAQ: LHDX ) stock is taking a beating on Thursday after the company filed for Chapter 11 bankruptcy protection. To go along with that filing, Lucira Health says it intends to sell its business during the bankruptcy process.
2023-02-01 09:47:22 - Zacks Investment Research
5 Big Winners as Wall Street Wraps Up Strong January Gains
AppHarvest (APPH), Lucira Health (LHDX), Lucid Group (LCID), Life Time Group (LTH) & Ameriprise Financial (AMP) not only have made the most of the January rally but also are poised to gain further this year.
2023-01-04 06:00:00 - PennyStocks
Biggest Penny Stocks Trading Mistakes to Avoid in 2023
Avoid making these penny stocks trading mistakes this year The post Biggest Penny Stocks Trading Mistakes to Avoid in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.